



April 2, 2024

Dear Partners,

As a valuable partner in HIV and STD prevention, we wanted to make you aware that Bavarian Nordic, the maker of [JYNNEOS](#), has [opened ordering of the vaccine through commercial wholesalers](#).

To ensure equitable access to JYNNEOS, health departments can continue to use the supply previously ordered from HHS and order the vaccine from the HHS supply to support access where commercial product is not yet available or accessible. Please note any requests or orders to the U.S. Department of Health and Human Services (HHS) should only be made in these circumstances where commercial product is not available or accessible.

On April 30, 2024, at 9 a.m. ET, HHS will close the current mechanism of ordering against thresholds by setting all thresholds to zero. If a provider requires additional supply after that date in circumstances where commercial supply is not available or accessible, JYNNEOS will be available by request using the established out-of-cycle request process. Ordering of the HHS-procured JYNNEOS is anticipated to fully close in early-to-mid-August 2024.

HHS and CDC will continue to update our state, local, tribal, and territorial partners on readiness of additional immunization program support, such as through [Vaccines for Children](#) (VFC) or 317 programs.

Thanks to your efforts, more than 1.2 million doses of the JYNNEOS vaccine were administered by the end of 2023 which—coupled with temporary changes to behavior during the 2022 mpox outbreak—helped bring the number of cases down from a peak of more than 450 a day in August 2022 to only a handful per day now.

Vaccination remains an important tool in stopping the spread of mpox. While great progress has been made in mpox vaccination, it is underutilized. Only about 1 in 4 people eligible for the JYNNEOS vaccine have received it. With many communities planning public health activities in conjunction with Pride and other summer events, encouraging both doses of the JYNNEOS vaccine may be key to preventing a new surge in cases.

At this time, we do not have information on costs associated with commercialization of JYNNEOS. HHS, CDC, and ASPR are working closely with Bavarian Nordic to determine out-of-pocket costs, insurance coverage, and access for people who are uninsured and underinsured.

Thanks for all that you do. Additional information will be available on the HHS website in the coming weeks, and please contact your [ASPR Regional Administrator](#) with any questions.



**Centers for Disease Control and Prevention**

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

[Questions or Problems](#) | [Unsubscribe](#)